Condition 1: Follicular lymphoma. Condition 2: Hodgkin lymphoma. Condition 3: Non-follicular lymphoma. Condition 4: Multiple myeloma and malignant plasma cell neoplasms. Follicular lymphoma Hodgkin lymphoma Non-follicular lymphoma Multiple myeloma and malignant plasma cell neoplasms
Conditions
Interventions
Intervention 1: Intervention:
Atorvastatin 40 mg daily PO started from the first day of hospitalization and continued until the day of cell harvest plus standard filgrastim regimen. Intervention 2: Co
Treatment - Drugs
Placebo
Intervention:
Atorvastatin 40 mg daily PO started from the first day of hospitalization and continued until the day of cell harvest plus standard filgrastim regimen
Control:
Placebo once daily PO started from the first day of hospitalization and continued until the day of cell harvest plus standard filgrastim regimen
Sponsors
Vice Chancellor for Research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 139 Years
Inclusion criteria
Inclusion criteria: Major inclusion criteria: Age equals to or greater than 18; Primary diagnosis consist of Hodgkin's lymphoma, Non-Hodgkin's lymphoma or Multiple Myeloma; Patient endorsement of informed consent Major exclusion criteria: Patients taking any statin drug at the time of enrollment; Occurrence of suspected drug related toxicity during treatment
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean number of hematopoietic progenitor cells per microliter of peripheral blood. Timepoint: Baseline, at the time of cell harvest. Method of measurement: Number of cells by flowcytometry assessment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time of platelet recovery. Timepoint: Any time after transplantation in which platelet engraftment occurs. Method of measurement: Complete blood count test.;Time of polymorphonuclear recovery. Timepoint: Any time after transplantation in which polymorphonuclear recovery occurs. Method of measurement: Complete blood count test.;Occurrence of bleeding episodes. Timepoint: Any time after transplantation and before discharge. Method of measurement: Occurrence or non.;Occurrence of infection episodes. Timepoint: Any time after transplantation and before discharge. Method of measurement: Occurrence or non.;Mean dose of filgrastim for stem cell mobilization. Timepoint: Before cell harvest. Method of measurement: Sum of administered doses.;Mean dose of filgrastim for engraftment. Timepoint: After transplantation until discharge. Method of measurement: Sum of administered doses.;Duration of hospitalization. Timepoint: From the day of stem cell infusion until the day of discharge. Method of measurement: Number of days.;Mortality. Timepoint: From the day of stem cell infusion until the day of discharge. Method of measurement: Occurrence or non. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMolouk Hadjibabaie
Research Center for Rational Use of Drugs
Outcome results
None listed